Nucs AI is an innovative company founded in 2024, dedicated to transforming cancer care through advanced AI and medical imaging technologies. With a multidisciplinary team of oncologists, AI researchers, and healthcare innovators, Nucs AI addresses the critical need for accurate and timely cancer diagnostics amidst increasing scan volumes and limited radiologist capacity. The company focuses on developing AI-powered tools that integrate medical imaging, radioligand therapy, and artificial intelligence, starting with prostate cancer and expanding across oncology. Partnering with leading medical institutions and pharmaceutical companies globally, Nucs AI aims to enhance diagnostic precision and broaden access to expert-level cancer care, ultimately improving patient outcomes worldwide. As a venture-backed, early-stage organization, Nucs AI is building a dynamic team that combines clinical expertise with engineering excellence to meet the demands of the medical field.